NCT04911894View on ClinicalTrials.gov

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

January 30, 2023

Study Completion Date

February 17, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

IBI321

Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY